We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
-4.68%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$17.7B
AUM Growth
-$815M
Cap. Flow
+$169M
Cap. Flow %
0.95%
Top 10 Hldgs %
18.06%
Holding
3,210
New
168
Increased
1,509
Reduced
1,241
Closed
160

Sector Composition

Rank Sector Weight
1 Technology 8.86%
2 Financials 4.76%
3 Consumer Discretionary 4.5%
4 Healthcare 4.18%
5 Consumer Staples 2.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MVST icon
3001
Microvast
MVST
$354M
$18K ﹤0.01%
10,010
NAK
3002
Northern Dynasty Minerals
NAK
$953M
$18K ﹤0.01%
74,160
+36,060
+95% +$10.3K
HYZN
3003
DELISTED
Hyzon Motors Inc. Class A Common Stock
HYZN
$18K ﹤0.01%
213
PXLW icon
3004
Pixelworks
PXLW
$42.3M
$17K ﹤0.01%
888
+41
+5% +$979
ZTEK
3005
Zentek
ZTEK
$79.7M
$17K ﹤0.01%
10,500
HYRE
3006
DELISTED
HyreCar Inc. Common Stock
HYRE
$16K ﹤0.01%
16,883
-181
-1% -$169
LMDX
3007
DELISTED
LumiraDx Limited Common Shares
LMDX
$15K ﹤0.01%
14,902
VHC icon
3008
VirnetX Holding Corp
VHC
$65.8M
$14K ﹤0.01%
591
-50
-8% -$1.61K
OIG
3009
DELISTED
Orbital Infrastructure Group, Inc. Common Stock
OIG
$14K ﹤0.01%
737
DMK
3010
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$13K ﹤0.01%
919
CRBP icon
3011
Corbus Pharmaceuticals
CRBP
$189M
$12K ﹤0.01%
2,461
+14
+0.6% +$99
UAMY icon
3012
United States Antimony
UAMY
$736M
$12K ﹤0.01%
+33,000
New +$14.4K
VYNT
3013
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$12K ﹤0.01%
+4,292
New +$16.2K
GLMD icon
3014
Galmed Pharmaceuticals
GLMD
$4.63M
$11K ﹤0.01%
195
+44
+29% +$3.75K
USAS
3015
Americas Gold and Silver
USAS
$1.75B
$11K ﹤0.01%
10,864
-27,898
-72% -$35.5K
SIEN
3016
DELISTED
Sientra, Inc.
SIEN
$10K ﹤0.01%
1,489
VSTM icon
3017
Verastem
VSTM
$629M
$9K ﹤0.01%
871
-4,004
-82% -$55.9K
ASXC
3018
DELISTED
Asensus Surgical, Inc.
ASXC
$9K ﹤0.01%
20,971
STAB
3019
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$9K ﹤0.01%
68,825
ANY icon
3020
Sphere 3D
ANY
$18.3M
$7K ﹤0.01%
212
-17
-7% -$771
FEED
3021
ENvue Medical Inc
FEED
$3.79M
$7K ﹤0.01%
7
+1
+17% +$1.3K
ORBS
3022
Eightco Holdings
ORBS
$286M
$7K ﹤0.01%
43
BIOR
3023
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$7K ﹤0.01%
60
SMTS
3024
DELISTED
Sierra Metals Inc. Common Stock
SMTS
$7K ﹤0.01%
14,902
+3,281
+28% +$1.88K
CFMS
3025
DELISTED
Conformis, Inc. Common Stock
CFMS
$7K ﹤0.01%
1,524

Similar funds

Cambridge Investment Research Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Cambridge Investment Research Advisors held 3,210 positions worth $17.7B, down 4.4% from $18.6B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Cambridge Investment Research Advisors's Q3 2022 filing shows 168 new, 1,509 increased, 1,241 reduced and 160 closed positions. Its largest new stake was JPMorgan BetaBuilders US Equity ETF: 201,011 shares worth $12.9M. The largest sale was iShares S&P Small-Cap 600 Value ETF, an estimated $46M.

By sector, the portfolio is most concentrated in Technology at 8.9% of assets, down from 9% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Cambridge Investment Research Advisors's largest Q3 2022 buy was JPMorgan BetaBuilders US Equity ETF: 201,011 shares worth $12.9M.
  • Cambridge Investment Research Advisors added most to First Trust Enhanced Short Maturity ETF in Q3 2022, an estimated $41.2M increase.
  • Cambridge Investment Research Advisors's biggest Q3 2022 reduction was iShares S&P Small-Cap 600 Value ETF, cutting an estimated $46M.
  • Cambridge Investment Research Advisors fully exited Invesco DB Energy Fund in Q3 2022, selling an estimated $5.88M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 18% of its $17.7B portfolio in Q3 2022.
  • Cambridge Investment Research Advisors opened 168 new positions and closed 160 in Q3 2022.
  • Cambridge Investment Research Advisors's portfolio value fell 4.4% quarter-over-quarter to $17.7B.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.